Andreas Freidig

Andreas Freidig currently serves as the R&D PMO Lead for Oncology and Director of R&D Project Management at Galapagos, where he plays a pivotal role in shaping the company's oncology research and development strategy. In this capacity, Andreas leverages his extensive expertise in project management methodologies to oversee complex early and late-stage drug development programs, ensuring seamless coordination across cross-functional teams. His leadership within the Oncology Leadership Team underscores his strategic influence in driving innovative solutions in areas such as cell therapy, gene therapy, and targeted oncology treatments.

At Galapagos, Andreas is instrumental in streamlining project workflows, implementing best practices for regulatory filings, and fostering a collaborative environment that accelerates decision-making processes. His deep understanding of the biopharmaceutical landscape enables him to manage relationships effectively across global regulatory agencies, clinical development partners, and internal stakeholders. Andreas’s focus on result-oriented project execution ensures that key milestones are met on time and within scope, ultimately advancing the company's pipeline and therapeutic objectives.

His role also involves guiding teams through the complexities of regulatory pathways, optimizing resource allocation, and integrating emerging scientific insights into project plans. With a proven track record of managing diverse teams in both large and small biotech companies, Andreas’s leadership is characterized by a strategic vision combined with operational excellence. His expertise in oncology, cell therapy, and gene therapy positions him as a key driver in Galapagos’s mission to develop transformative medicines for patients worldwide.